Intuity Medical is a technology company.
Intuity Medical has raised $224.0M across 7 funding rounds.
Intuity Medical has raised $224.0M in total across 7 funding rounds.
Intuity Medical is a commercial-stage medical technology company founded in 2002, specializing in innovative diabetes management solutions, particularly the POGO Automatic Blood Glucose Monitoring System—the first FDA-approved automatic blood glucose monitor that lances, collects, and analyzes blood in one step using a 10-test cartridge[2][5][6]. It serves people with diabetes, especially insulin users requiring 3-8 tests daily, healthcare providers (HCPs), and payers by addressing poor adherence to testing regimens, which hinders effective diabetes management and glycemic control[1][2]. The system solves key problems like handling separate lancets and strips, disposal hassles, and disruption to daily life, offering easy one-step testing, Bluetooth sync to the Patterns app for data insights, and clinically proven A1C reduction in three months, positioning it between low-adherence traditional meters and high-cost continuous glucose monitors (CGMs)[1][2][5].
With 111 employees based in Fremont, California, the company has shown growth momentum through FDA clearance in 2016 and a US launch, though it faced challenges including a withdrawn NASDAQ IPO under symbol POGO and recent financials of $0.07M revenue against -$48.23M net income over the last 12 months[2][5][6].
Intuity Medical was founded in 2002 in Fremont, California, as a medtech innovator focused on advanced diabetes management systems[3][6]. While specific founders are not detailed in available records, the company emerged from the need to simplify blood glucose monitoring, a critical yet burdensome routine for diabetes patients requiring frequent testing[1][2]. A pivotal moment came in April 2016 when the FDA granted 510(k) clearance (K162203) for the POGO Automatic system, deeming it substantially equivalent to the predicate Contour Next EZ meter after three clinical studies validating its accuracy, including lay user evaluations and reapplication mode testing[5]. Early traction built on consumer-driven demand for less invasive, adherent-friendly tools, leading to the US commercial launch highlighted by CEO Emory Anderson for its life-disrupting simplicity[2][4].
Intuity Medical stands out in the diabetes tech space through the POGO Automatic system's unique automation and user-centric design:
These features position POGO as best-in-class for bridging gaps in the care continuum[1].
Intuity Medical rides the wave of digital health and medtech innovation in diabetes management, where frequent monitoring is essential but traditional fingerstick meters suffer from low adherence (often <3 tests/day) and CGMs face high costs and sensor resistance[1][2]. Timing aligns with rising diabetes prevalence and payer emphasis on outcomes like A1C reduction to cut complications and costs, amplified by post-2016 FDA validation enabling US market entry[1][5]. Market forces favoring integrated, patient-friendly devices—proven in clinical studies—position it to influence the ecosystem by boosting testing compliance, providing actionable data to HCPs, and challenging incumbents with superior ease-of-use[1][2][5]. As a withdrawn IPO candidate, it highlights funding dynamics in medtech amid revenue scaling pressures[6].
Intuity Medical's POGO Automatic could scale by expanding cartridge distribution, app integrations, and international markets, capitalizing on trends like AI-driven diabetes insights and value-based care demanding adherence tools[1][2]. Evolving reimbursement for automated systems and competition from CGM advancements will shape its path, potentially via partnerships or renewed public listing post-financial turnaround[6]. Its influence may grow by humanizing diabetes management—turning disruptive testing into seamless habit—echoing the core promise of simplifying life for millions with diabetes[2][4].
Intuity Medical has raised $224.0M in total across 7 funding rounds.
Intuity Medical's investors include Hercules Capital, U.S. Venture Partners, Acorn Bioventures, Aisling Capital, Casey Tansey.
Intuity Medical has raised $224.0M across 7 funding rounds. Most recently, it raised $70.0M Venture Round in January 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2018 | $70.0M Venture Round | Hercules Capital, U.S. Venture Partners | |
| Nov 1, 2016 | $40.0M Venture Round | Acorn Bioventures, Aisling Capital, Hercules Capital, Casey Tansey, U.S. Venture Partners | |
| Jan 1, 2014 | $6.0M Venture Round | Acorn Bioventures, Aisling Capital, Hercules Capital, Casey Tansey, U.S. Venture Partners | |
| Aug 1, 2012 | $12.0M Venture Round | Acorn Bioventures, Aisling Capital, Hercules Capital, Casey Tansey | |
| Jul 1, 2011 | $12.0M Series D | Acorn Bioventures, Aisling Capital, Hercules Capital, Casey Tansey, U.S. Venture Partners | |
| Jan 1, 2010 | $64.0M Series D | Acorn Bioventures, Aisling Capital, Hercules Capital, Casey Tansey, U.S. Venture Partners | |
| Aug 1, 2006 | $20.0M Series C | U.S. Venture Partners |